Previous close | 1,253.75 |
Open | 1,256.95 |
Bid | 1,298.00 x 0 |
Ask | 1,298.05 x 0 |
Day's range | 1,254.90 - 1,311.00 |
52-week range | 723.40 - 1,311.00 |
Volume | |
Avg. volume | 50,766 |
Market cap | 763.756B |
Beta (5Y monthly) | 0.55 |
PE ratio (TTM) | 24.08 |
EPS (TTM) | 54.16 |
Earnings date | 10 Aug 2024 - 14 Aug 2024 |
Forward dividend & yield | 4.50 (0.36%) |
Ex-dividend date | 20 Feb 2024 |
1y target est | 762.03 |
Aurobindo Pharma (NS:ARBN) has outperformed expectations in the fourth quarter of FY24, with both sales and EBITDA showing significant year-over-year growth. Sales increased by 17%, while EBITDA surged by an impressive 68%, surpassing both Goldman Sachs (NYSE:GS)' projections and those of the broader market. The EBITDA margin also exceeded forecasts, reaching 22.3%, which is 101 basis points higher than Goldman Sachs' estimate.